Eli Lilly's oral weight loss drug Orforglipron clinical trial data missed expectations, causing stock price to plummet - To The Moon

NewsNews
PostsPosts
SelectionSelection

- JIANG_LIMJIANG_LIM
  ·2025-08-08
  $Eli Lilly(LLY)$ Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.
  2.98K 6
  71
  Share
  Report

{"themeInfo":{"themeId":"d1cafebee0487e6693a2bb06c4e28c89","name":"Eli Lilly's oral weight loss drug Orforglipron clinical trial data missed expectations, causing stock price to plummet","description":"Eli Lilly announced that the clinical trial data of the oral weight loss drug Orforglipron failed to meet market expectations, and the stock price fell nearly 14%. Shares of rival Novo Nordisk rose 6% as the market focused on competition in the GLP-1 obesity drug market.","image":"https://community-static.tradeup.com/news/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1754579186299,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":d1cafebee0487e6693a2bb06c4e28c89}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowSubscriptionFinancial":false,"subscriberCount":0,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["NVO","LLY"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Eli Lilly's oral weight loss drug Orforglipron clinical trial data missed expectations, causing stock price to plummet","tweetAmount":1,"imageIsDefault":false,"aiDerivativeIssues":[]},"tab":"essen","isFinancial":true,"allList":[{"id":465178456023192,"gmtCreate":1754594212806,"gmtModify":1754623549692,"author":{"id":"3576230765100636","authorId":"3576230765100636","name":"JIANG_LIM","avatar":"https://community-static.tradeup.com/news/4d47a70c049ddba8a088792dd737f669","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3576230765100636","idStr":"3576230765100636"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.","listText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.","text":"$Eli Lilly(LLY)$ Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":71,"commentSize":6,"repostSize":12,"link":"https://ttm.financial/post/465178456023192","isVote":1,"tweetType":1,"viewCount":2975,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010955","authorId":"10000000000010955","name":"Porter Harry","avatar":"https://static.tigerbbs.com/6b5dd5252a1bca34909f191e8c9ba404","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"10000000000010955","idStr":"10000000000010955"},"content":"Spot on on $LLY — a harsh reality check for a stock priced to perfection.","text":"Spot on on $LLY — a harsh reality check for a stock priced to perfection.","html":"Spot on on $LLY — a harsh reality check for a stock priced to perfection."},{"author":{"id":"10000000000010993","authorId":"10000000000010993","name":"Enid Bertha","avatar":"https://static.tigerbbs.com/a539edbf3388702a82cb1d4728704766","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"10000000000010993","idStr":"10000000000010993"},"content":"the treat has lost all confidence in lly ability to continue it ridiculous business model! the model is a joke nd i predicted that more the 8 months go","text":"the treat has lost all confidence in lly ability to continue it ridiculous business model! the model is a joke nd i predicted that more the 8 months go","html":"the treat has lost all confidence in lly ability to continue it ridiculous business model! the model is a joke nd i predicted that more the 8 months go"}],"imageCount":0,"langContent":"EN","totalScore":0}],"essenList":[],"allBottom":false,"essenBottom":true}